{"disease":{"id":"kras-gene-mutation","name":"kras gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03065387","title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":93,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06270082","title":"Study of IK-595 in RAS- or RAF-altered Advanced Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":75,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT03829410","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Cardiff Oncology","has_results":true},{"nct_id":"NCT02642042","title":"Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03087071","title":"Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03965845","title":"A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":false},{"nct_id":"NCT03750175","title":"OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -","phase":"","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Karen-Lise Garm Spindler","has_results":false},{"nct_id":"NCT04965818","title":"Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT03777124","title":"Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03520842","title":"Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT04976439","title":"Patogenic Mutation in 5 Genes","phase":"","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Dr Cipto Mangunkusumo General Hospital","has_results":false},{"nct_id":"NCT04117945","title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT06229340","title":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"N.N. Petrov National Medical Research Center of Oncology","has_results":false},{"nct_id":"NCT02964689","title":"Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT03808558","title":"Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"David E Gerber","has_results":false},{"nct_id":"NCT03299088","title":"Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Jonathan Riess","has_results":true},{"nct_id":"NCT03704688","title":"Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT04566393","title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT04446793","title":"Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Cardiff Oncology","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}